Navigation Links
FDA grants Genentech's Perjeta® (pertuzumab) accelerated approval for use before surgery in people with HER2-positive early stage breast cancer
Date:10/1/2013

(September 30, 2013) The U.S. Food and Drug Administration (FDA) granted accelerated approval of a Perjeta (pertuzumab) regimen for neoadjuvant treatment (use before surgery) in people with high-risk, HER2-positive early stage breast cancer.

This approval is based primarily on data from a Phase II study showing that nearly 40 percent of people receiving the combination of Perjeta, Herceptin (trastuzumab) and docetaxel chemotherapy had no evidence of tumor tissue detectable at the time of surgery (known as a pathological complete response, or pCR). The most common severe (Grade 3 or higher) AEs for the Perjeta regimen were neutropenia (decrease in a certain type of white blood cell, 44.9 percent), febrile neutropenia (fever associated with decrease in a certain type of white blood cell, 8.4 percent), leukopenia (decrease in overall white blood cells, 4.7 percent) and diarrhea (5.6 percent).

This new neoadjuvant indication for Perjeta is for use prior to surgery in combination with Herceptin and docetaxel chemotherapy in people with HER2-positive, locally advanced, inflammatory, or early stage (tumor is greater than two centimeters in diameter or node positive) breast cancer. Perjeta should be used as part of a complete treatment regimen for early stage breast cancer. This use of Perjeta is based on an improvement in the percentage of people who had no evidence of cancer in the breast or lymph nodes at the time of surgery. Currently, no data have shown whether or not treatment with Perjeta prior to surgery improves survival. The safety of Perjeta as part of a doxorubicin (chemotherapy)-containing regimen has not been established. The safety of Perjeta administered for greater than six cycles for early stage breast cancer has not been established. Please see Perjeta full Prescribing Information including Most Serious Side Effects for additional Important Safety Information at http://www.perjeta.com.

Background on Neoadjuvant Treatment:

Upon receiving an early stage breast cancer diagnosis, a person typically undergoes surgery and may then receive a medicine in the "adjuvant" (post-surgery) setting. Neoadjuvant treatment is another treatment option given after diagnosis but before surgery. Neoadjuvant treatment may allow a doctor to quickly access whether a medicine is working, and may also reduce a tumor's size so it is easier to surgically remove.

WHY THIS APPROVAL IS IMPORTANT

  • Treating people with breast cancer early, before the cancer has spread, may offer the best chance of preventing the disease from returning.
  • The Perjeta regimen is the first treatment approved under a new FDA pathway for neoadjuvant use in breast cancer.
  • This new approval pathway makes Perjeta available to people with high-risk, early stage breast cancer more quickly than is possible with traditional approvals.
  • HER2-positive breast cancer is a particularly aggressive form of the disease that affects approximately 25 percent of people with breast cancer.


'/>"/>

Contact: Russell Grant
grantr@fleishman.com
212-453-2430
Fleishman-Hillard
Source:Eurekalert

Related medicine news :

1. Professors at Purchase College and Columbia University Receive More Than $500,000 in Grants to Study New Ways to Reduce Anxiety Disorders
2. Canon and Evergreen Help Thirty Community Groups Across Canada Plant Native Trees with $150,000 in Grants
3. Cashless Nigeria: Central Bank Of Nigeria Grants Globasure Approval to Operate as a Payment Terminal Service Provider (PTSP)
4. American Brain Tumor Association Seeks Inventive Ideas for Research Discovery Grants
5. 2 Georgia cancer patient support organizations to receive Survivor Circle grants from ASTRO
6. Life Sciences Discovery Fund announces $3.7m in research and development grants
7. Mount Sinai Grants Exclusive License to Plexcera Therapeutics to Develop Treatments for Farber Disease and Cystic Fibrosis
8. New NIH grants to investigate disease-related variations in genetic makeup
9. NIH grants Brown University $11M for brain research
10. ASTRO awards $34,500 in individual grants to top researchers presenting at the 2013 Annual Meeting
11. ASTRO to award $675,000 in junior faculty research grants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... is proud to recognize Dr. Barry M. Weintraub as a prominent plastic surgeon ... beautiful women in the world, and the most handsome men, look naturally attractive. ...
(Date:6/24/2016)... Frederick, Maryland (PRWEB) , ... June 24, 2016 ... ... Mid-Atlantic Angels is actively feeding the Frederick area economy by obtaining investment capital ... support over the past 2½ years that have already resulted in more than ...
(Date:6/24/2016)... ... June 24, 2016 , ... Venture Construction Group (VCG) ... held on June 20th at the Woodmont Country Club at 1201 Rockville Pike, ... organization dedicated to helping service members that have been wounded in battle and their ...
(Date:6/24/2016)... , ... June 24, 2016 , ... ... supporting the upcoming 2016 Miss Arizona pageant as its official Medspa Sponsor. Dr. ... Tempe, Mesa, and Chandler, Arizona. , Dr. Olson says the decision to ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... , June 24, 2016  American Respiratory Labs (ARL), a ... now able to perform sophisticated lung assessments in patients, homes, thanks ... Inc. Patients are no longer limited to having ... PRO ® , ARL patients like Jeanne R. of ... the comfort of her own home. ...
(Date:6/24/2016)... June 24, 2016 According to ... Type (Standard Pen Needles, Safety Pen Needles), Needle Length ... Growth Hormone), Mode of Purchase (Retail, Non-Retail) - Trends ... report studies the market for the forecast period of ... USD 2.81 Billion by 2021 from USD 1.65 Billion ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology: